SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Anonymous. Carbamazepine in the management of seizure disorders. Med Lett Drugs Ther 1975;17:76.
  • 2
    Simonsen N, Olsen PZ, Kuhl V, Lund M, Wendelboe J. A double blind study of carbamazepine and diphenylhydantoin in temporal lobe epilepsy. Acta Neurol Scand [suppl] 1975;60:3942.
    Direct Link:
  • 3
    Smith DB, Mattson RH, Cramer JA, Collins IF, Novelly RA, Craft B. Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia 1987;28(suppl 3):S508.
  • 4
    Geradin AP, Abadie FV, Campestrini JA, Theobald W. Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses. J Pharmacokinet Biopharm 1976;4:52135.
  • 5
    McKauge L, Tyrer JH, Eadie MJ. Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma. Ther Drug Monit 1981;3:6370.
  • 6
    Levy RH, Wurden CJ. Carbamazepine: interactions with other drugs. In: LevyRH, MattsonRH, MeldrumBS, eds. Antiepileptic drugs. New York : Raven Press, 1995;54354.
  • 7
    Stanaway L, Lambie DG, Johnson RH. Non-compliance with anticonvulsant therapy as a cause of seizures. NZ Med J 1985;98:1502.
  • 8
    Shope JT. Compliance in children and adults: review of studies. Epilepsy Res 1988; 1(suppl) 2347.
  • 9
    Loiseau P, Marchal C. Determinants of compliance in epileptic patients. Epilepsy Res 1988;1 (suppl):13540.
  • 10
    Kurokawa T, Minami T, Kitamoto I, Mizuno Y, Maeda Y, Takaki S. Compliance in epileptic children in Japan. Epilepsy Res 1988; 1(suppl): 14751.
  • 11
    Alonso NB, da Silva DF, Pereira SD, de Campos CJ. Compliance in epilepsy. II. Practical aspects. Arq Neuropsiquiatr 1991;49:1504.
  • 12
    Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:32737.
  • 13
    Leppik IE, CIoyd J, Sawchuk RJ. Coefficient of variation as measure of compliance [Letter]. Lancer 1978;2:849.
  • 14
    Jensen PK, Moller A, Gram L, Jensen NO, Dam M. Pharmacokinetic comparison of two carbamazepine slow-release formulations. Acta Neurol Scand 1990;82:1357.
  • 15
    Faigle JW, Feldmann FK. Carbamazepine: chemistry and biotransformation. In: LevyRH, MattsonRH. MeldumBS, eds. Antiepileptic drugs, 4th ed. New York : Raven Press, 1995;499513.
  • 16
    Kern BM, Levy KH. Carbamazepine epoxide. In: LevyRH, MattsonRH, MeldurnBS, eds. Antiepileptic drugs, 4th ed. New York : Raven Press, 1995;52941.
  • 17
    Steinijans VW, Hawk WW, Diletti E, Hauschke D, Anderson S. Effect of changing the bioequivalence range from (0.80, 1.20) to (0.80, 1.25) on the power and sample size. Int J Clin Pharmacol Ther Toxicol 1992;30:5715.
  • 18
    Chen M-L, Patnaik R. Guidance on statistical procedures for bioequivalence studies using a standard two-treatment crossover design. Rockville MD : The Division of Binequivalence, Office of Generic Drugs. US Food and Drug Administration: 1992.